Private fee-for-service (PFFS) plans are the fastest growing, and most controversial, aspect of the Medicare Advantage (MA) program. They account for approximately 18% of total enrollment, and according to MedPAC, they are receiving payments that average 19% more than payments to traditional Medicare.
Private fee-for-service (PFFS) plans are the fastest growing, and most controversial, aspect of the Medicare Advantage (MA) program. They account for approximately 18% of total enrollment, and according to MedPAC, they are receiving payments that average 19% more than payments to traditional Medicare.
Private fee-for-service (PFFS) plans were created by the Balanced Budget Act of 1997 (BBA), and then modified by the Medicare Modernization Act of 2003 (MMA). They resemble a privately-administered version of traditional fee-for-service Medicare. They're exempt from many of Medicare's requirements for HMOs and PPOs; they are not required to create provider networks. While they receive capitated payments, they pay providers on a fee-for-service basis.
In recent years, PFFS plans have grown dramatically. From December 2005 to February 2007, enrollment in HMOs and PPOs increased from 5.1 million to 6 million, a growth rate of 18%. During the same period, enrollment in PFFS plans increased from 208,990 enrollees to 1.3 million, a growth rate of 535%. Most of this growth focused on counties with rural or urban floors, where the difference between federal payments for traditional Medicare and MA is greatest.
In June, the Centers for Medicare and Medicaid Services announced that seven insurers (representing 90% of the non-group PFFS market) had voluntarily agreed to suspend marketing of PFFS plans. The suspension will be lifted for each plan only after CMS verifies that the plan has appropriate systems and management controls in place, including verification of the beneficiary's intent to enroll, and documented training of marketing agents and brokers. Legislation has been introduced in Congress that would allow state insurance commissioners to develop standardized marketing regulations for Medicare Advantage plans.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Early Genetic Testing Avoids Treatment Delays for Patients with Friedreich Ataxia
September 18th 2024Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.
Read More